UCB Stock Forecast, Price & News

+0.51 (+1.08 %)
(As of 04/14/2021 12:00 AM ET)
Today's Range
Now: $47.73
50-Day Range
MA: $48.07
52-Week Range
Now: $47.73
Volume8,188 shs
Average Volume20,907 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, nayzilam, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; bimekizumab for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition , the company is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis immune-mediated necrotizing myopathy; staccato alprazolam to treat active epileptic seizure; and UCB0107 to treat tauopathies and progressive supranuclear palsy. Further, it engages in contract manufacturing activities. The company has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was founded in 1928 and is headquartered in Brussels, Belgium.
UCB logo

Industry, Sector and Symbol

Industry Biotechnology
Phone32 2 559 99 99
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Next Earnings DateN/A
OptionableNot Optionable


UCB SA (OTCMKTS:UCBJY) Short Interest Down 81.2% in March
April 13, 2021 |  americanbankingnews.com
UCB SA (OTCMKTS:UCBJY) Short Interest Update
April 1, 2021 |  americanbankingnews.com
UCB : UCB SA/NV - Convening notice annual shareholders meeting
March 31, 2021 |  markets.businessinsider.com
See More Headlines


Overall MarketRank

0.52 out of 5 stars

Medical Sector

1503rd out of 2,019 stocks

Biotechnology Industry

76th out of 145 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
+0.51 (+1.08 %)
(As of 04/14/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UCBJY News and Ratings via Email

Sign-up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

UCB (OTCMKTS:UCBJY) Frequently Asked Questions

Is UCB a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" UCB stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UCBJY, but not buy additional shares or sell existing shares.
View analyst ratings for UCB
or view top-rated stocks.

What stocks does MarketBeat like better than UCB?

Wall Street analysts have given UCB a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but UCB wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting UCB?

UCB saw a decline in short interest during the month of March. As of March 31st, there was short interest totaling 2,500 shares, a decline of 81.2% from the March 15th total of 13,300 shares. Based on an average daily volume of 44,700 shares, the days-to-cover ratio is currently 0.1 days.
View UCB's Short Interest

How has UCB's stock been impacted by Coronavirus?

UCB's stock was trading at $50.3225 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, UCBJY shares have decreased by 5.2% and is now trading at $47.7250.
View which stocks have been most impacted by COVID-19

Who are UCB's key executives?

UCB's management team includes the following people:
  • Mr. Jean-Christophe Tellier, CEO & Exec. Director (Age 62)
  • Ms. Kirsten Lund-Jurgensen, Exec. VP of Supply & Technology Solutions (Age 62)
  • Dr. Dhavalkumar D. Patel Ph.D., M.D., Exec. VP & Chief Scientific Officer (Age 60)
  • Mr. William J. Silbey, Exec. VP & Gen. Counsel (Age 62)
  • Mr. Jean-Luc Fleurial, Exec. VP & Chief HR Officer (Age 56)
  • Prof. Iris Löw-Friedrich, Chief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VP (Age 61)
  • Mr. Emmanuel Caeymaex, Exec. VP of Immunology Solutions & Head of US (Age 52)
  • Mr. Charl Van Zyl, Exec. VP of Neurology Solutions & Head of EU/International (Age 54)
  • Ms. Sandrine Dufour, Exec. VP & CFO (Age 54)
  • Ms. Caroline Vancoillie, Chief Accounting Officer & CFO of Patient Value Functions

Who are some of UCB's key competitors?

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJY."

How do I buy shares of UCB?

Shares of UCBJY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is UCB's stock price today?

One share of UCBJY stock can currently be purchased for approximately $47.73.

How many employees does UCB have?

UCB employs 7,820 workers across the globe.

What is UCB's official website?

The official website for UCB is www.ucb.com.

How can I contact UCB?

The company can be reached via phone at 32 2 559 99 99.

This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.